Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.35 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23104539 | 0.89 | P2RX7 (0.41) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL30636533 | 0.86 | PRKAB2 (0.37) | P2RX7NAPRTPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL20972234 | 0.86 | PRKAB2 (0.37) | P2RX7NAPRTPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL31463672 | 0.81 | DGAT1 (0.41) | P2RX7SLC6A4 | |
| SCHEMBL17080583 | 0.78 | SLC6A2 (0.33) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL17080539 | 0.78 | HDAC6 (0.33) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL26418869 | 0.78 | GABRP (0.37) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL19849282 | 0.77 | P2RX7 (0.35) | P2RX7 | |
| SCHEMBL20489698 | 0.77 | P2RX7 (0.36) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL15129177 | 0.75 | SLC6A3 (0.59) | P2RX7SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025096979-A1 | THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025024707-A1 | INHIBITORS OF CDK2/4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025024665-A1 | TREATMENT OF CANCER WITH A CDK INHIBITOR | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-3372601-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3372601-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-09-12 | — | — | EP | disclosed |
| EP-1703908-A4 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1703908-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | AMGEN SF, LLC (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005063247-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | P2RX7 1975/4885SLC6A2 1272/4885SLC6A4 979/4885 |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | P2RX7 4521/4885SLC6A2 2889/4885SLC6A4 3645/4885 |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | TPMT, CYP11B2, ABAT | P2RX7 1975/4885SLC6A2 1272/4885SLC6A4 979/4885 |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | SULT2A1, ARSA, SULT1A1 | P2RX7 335/4885SLC6A2 564/4885SLC6A4 386/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | P2RX7 4574/4885SLC6A2 2924/4885SLC6A4 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.